Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
This is a study to demonstrate that different doses of once-weekly LY2189265 injected
subcutaneously will have dose proportional effect on hemoglobin A1c (HbA1c) at 12 weeks in
participants with type 2 diabetes mellitus.